Sjogren's syndrome: Current therapies remain inadequate for a common disease

Expert Opinion on Investigational Drugs

Volumn 9, Issue 9, 2000, Pages 2007-2016

  Fox, R I ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune; Autoimmunity of oral and ocular mucosa; Keratoconjunctivitis; Sjogren's syndrome

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTIFICIAL TEAR; CEVIMELINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FLUORIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LEVOFLOXACIN; METHOTREXATE; MUSCARINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; SALIVA SUBSTITUTE; ENZYME INHIBITOR; EYE DROPS; ISOXAZOLE DERIVATIVE;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRY EYE; EYE INFECTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; KERATOCONJUNCTIVITIS SICCA; LACRIMAL GLAND; LYMPHOMA; PATHOGENESIS; PERIPHERAL NEUROPATHY; REVIEW; RHEUMATOID ARTHRITIS; SALIVARY GLAND DISEASE; SCLERODERMA; SECRETION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOOTH DISEASE; VASCULITIS; XEROSTOMIA; ANIMAL; DENTAL CARIES; DRUG EFFECT; PATHOPHYSIOLOGY; SALIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; DENTAL CARIES; ENZYME INHIBITORS; HUMANS; ISOXAZOLES; OPHTHALMIC SOLUTIONS; SALIVATION; SJOGREN'S SYNDROME;

EID: 0033623321     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.9.2007     Document Type: Review

References (85)

1. Classification criteria for Sjogren's syndrome
2. Pathogenesis and treatment of Sjogren's syndrome
3. The genes of systemic autoimmunity
4. Epstein-Barr virus and human autoimmune diseases: Possibilities and pitfalls
5. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome
6. Low copy numbers of human T-cell lymphotropic virus Type I (HTLV-I) tax-like DNA detected in the salivary gland of seronegative patients with Sjogren's syndrome in an HTLV-I endemic area
7. Hepatitis C virus infections in 'primary' Sjogren's syndrome: Prevalence and clinical significance in a series of 90 patients
8. Sicca syndrome associated with hepatitis C virus infection
9. T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice
10. Current issues in the diagnosis and treatment of Sjogren's syndrome
11. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome
12. Bcl-2 family expression in salivary glands from patients with primary Sjogren's syndrome: Involvement of Bax in salivary gland destruction
13. Sjogren's syndrome. Pathogenesis and new approaches to therapy
14. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome
15. Granzyme Expression in Sjogren's Syndrome
16. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome
17. Subcellular organization of ion transporters in lacrimal acinar cells: Secretagogue-induced dynamics
18. Gene cloning of BM180, a lacrimal gland enriched basement membrane protein with a role in stimulated secretion
19. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix
20. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression
21. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line
22. Sjogren's syndrome. Controversies and progress
23. Dry eye: Pharmacological approaches, effects and progress
24. Adverse external ocular effects of topical ophthalmic medications
25. Prevalence of eyelid dermatitis in primary Sjogren's syndrome
26. Meibomian gland dysfunction
27. Role of staphylococcal toxin production in blepharitis
28. Assessment of keratoconjunctivitis sicca in patients with fibromyalgia: Results of a prospective study
29. Blepharitis - A diagnostic and therapeutic challenge. A report on 407 consecutive cases
30. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci
31. Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer
32. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease
33. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: The effect of topical Cyclosporin A therapy
34. Ophthalmic cyclosporine in equine keratitis and keratouveitis: 11 cases
35. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber
36. Oral manifestations in patients with Sjogren's syndrome
37. Xerostomia: A prevalent condition in the elderly
38. Association of patterns of labial salivary gland inflammation with keratocon-junctivitis sicca. Analysis of 618 patients with suspected Sjogren's syndrome
39. Sjogren's syndrome: Oral and dental considerations
40. Effects of fluoride-and chlorhexidine-containing varnishes on plaque composition and on demineralization of dentinal grooves in situ
41. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction
42. Effectiveness of pilocarpine in postradiation xerostomia
43. Radiotherapy for head and neck cancers including chemoradiotherapy
44. Pilocarpine Tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial
45. Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome
46. The use of oral pilocarpine in xerostomia and Sjogren's syndrome
47. Randomized, placebo controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjogren's syndrome
48. Sialogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjorgen's syndrome
49. Salivary mucins in oral mucosal defense
50. The Doyne lecture. Reflections on the tears
51. Polydispersity of normal human conjunctival mucins
52. Secreted and membrane bound ocular mucins from normal and dry eye dogs
53. Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin and histatins
54. Salivary mucous glycoprotein MG1 in Sjogren's syndrome
55. Molecular cloning and characterization of the gene encoding rat submandibular gland apomucin, Mucsmg
56. Cloning and expression of mouse UDP-Ga1NAc: Polypeptide N-acetylgalactos aminyltransferase-T3
57. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine
58. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: A Phase II clinical trial
59. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome
60. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection
61. Development of Sjogren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C
62. Treatment of primary Sjogren's syndrome with hydroxychloroquine: A retrospective, open-label study
63. Hydroxychloroquine treatment for primary Sjogren's syndrome: Its effect on salivary and serum inflammatory markers
64. Methotrexate in primary Sjogren's syndrome
65. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome
66. Cyclosporin A (CyA) in primary Sjogren's syndrome: A double blind study
67. Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjogren's syndrome
68. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases
69. Primary Sjogren's syndrome with severe central nervous system disease
70. Increased risk of lymphoma in sicca syndrome
71. Sjogren syndrome and pseudolymphoma
72. Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer
73. Lymphocyte phenotype and function of pseudolymphomas associated with Sjogren's syndrome
74. Sjogren's syndrome: New approaches to pathogenesis and therapy
75. A novel immunomodulating agent - Leflunomide inhibits exwperimental autoimmune diabetes in mice
76. Immunopharmacologic properties of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis in the rat
77. Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides
78. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group
79. Mechanism of action for leflunomide in rheumatoid arthritis
80. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-1pr/1pr mice
81. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
82. sTNFbp prevents development of lymphoid infiltrates in the NOD mouse, a model for human Sjogren's Syndrome
83. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
84. Review article: Safety of infliximab in clinical trials
85. Musculoskeletal and systemic reactions to biological therapeutic agents